CL2009002073A1 - Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares. - Google Patents
Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.Info
- Publication number
- CL2009002073A1 CL2009002073A1 CL2009002073A CL2009002073A CL2009002073A1 CL 2009002073 A1 CL2009002073 A1 CL 2009002073A1 CL 2009002073 A CL2009002073 A CL 2009002073A CL 2009002073 A CL2009002073 A CL 2009002073A CL 2009002073 A1 CL2009002073 A1 CL 2009002073A1
- Authority
- CL
- Chile
- Prior art keywords
- agent
- acidic agent
- active
- achiever
- pka
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Composición farmacéutica sólida para la liberación controlada de un agente activo en el tracto gastrointestinal que comprende al menos un agente ácido con solubilidad de menos de 0,3 mg/ml en solución acuosa a un Ph alrededor del pka del agente ácido, un polímero hidrófilo, un alcanizador; y su uso en trastornos cardiovasculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11494108P | 2008-11-14 | 2008-11-14 | |
US11500808P | 2008-11-14 | 2008-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009002073A1 true CL2009002073A1 (es) | 2010-12-24 |
Family
ID=41466672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009002073A CL2009002073A1 (es) | 2008-11-14 | 2009-11-13 | Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20100151019A1 (es) |
EP (1) | EP2376065A2 (es) |
JP (1) | JP2012508773A (es) |
KR (1) | KR20110097829A (es) |
CN (1) | CN102271663A (es) |
AR (1) | AR074347A1 (es) |
AU (1) | AU2009313867A1 (es) |
BR (1) | BRPI0921049A2 (es) |
CA (1) | CA2743639A1 (es) |
CL (1) | CL2009002073A1 (es) |
RU (1) | RU2011123377A (es) |
TW (1) | TW201022253A (es) |
WO (1) | WO2010057036A2 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
MX2010008138A (es) | 2008-01-25 | 2010-08-10 | Gruenenthal Gmbh | Forma de dosis farmaceutica. |
RU2508092C2 (ru) | 2008-05-09 | 2014-02-27 | Грюненталь Гмбх | Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки |
AR077493A1 (es) | 2009-07-22 | 2011-08-31 | Gruenenthal Gmbh | Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion |
WO2011009604A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
WO2011088152A1 (en) * | 2010-01-12 | 2011-07-21 | Portola Pharmaceuticals, Inc. | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
CN102821757B (zh) | 2010-02-03 | 2016-01-20 | 格吕伦塔尔有限公司 | 通过挤出机制备粉末状药物组合物 |
AR082862A1 (es) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
WO2012028319A1 (en) * | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US8987285B2 (en) * | 2010-12-03 | 2015-03-24 | Portola Pharmaceuticals, Inc. | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof |
KR20140053159A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
NO2736497T3 (es) | 2011-07-29 | 2018-01-20 | ||
BR112014004963A2 (pt) * | 2011-09-02 | 2017-03-21 | Novartis Ag | sal de colina do composto anti-inflamatório ciclobutanodiona substituído |
WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
PT2838512T (pt) | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping) |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
JP2015516406A (ja) | 2012-05-11 | 2015-06-11 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 亜鉛を含む熱成形された不正使用防止医薬剤形 |
DK2719376T3 (en) * | 2012-10-12 | 2015-06-15 | Omya Int Ag | Gastroretentiv drug formulation and delivery systems and their method of preparation by the use of functional calcium carbonate |
BR112015026549A2 (pt) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | forma de dosagem à prova de violação contendo uma ou mais partículas |
AR096439A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido que contiene una o más partículas |
KR20160031526A (ko) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형 |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
MA40071A (fr) * | 2014-07-01 | 2016-01-07 | Probi Usa Inc | Comprimés probiotiques bi-couche à double libération |
WO2016059583A1 (en) * | 2014-10-17 | 2016-04-21 | Fidia Farmaceutici S.P.A. | Dermal therapeutic system with high adhesivity |
JP6532153B2 (ja) * | 2015-01-30 | 2019-06-19 | ライオン株式会社 | 内服用錠剤 |
WO2016124530A1 (en) | 2015-02-03 | 2016-08-11 | Grünenthal GmbH | Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US10905726B2 (en) * | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10828340B2 (en) * | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
CN110869007B (zh) * | 2017-06-23 | 2022-10-14 | 太阳医药高级研究有限公司 | 防滥用的口服固体剂型 |
JP7158189B2 (ja) * | 2018-07-11 | 2022-10-21 | 東洋電装株式会社 | スロットルグリップ装置 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
EP1868581B1 (en) * | 2005-04-11 | 2012-03-14 | Abbott Laboratories | Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs |
EP1951254B1 (en) * | 2005-11-03 | 2012-01-04 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
NZ599556A (en) * | 2007-05-02 | 2013-10-25 | Portola Pharm Inc | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
-
2009
- 2009-11-13 EP EP09759842A patent/EP2376065A2/en not_active Withdrawn
- 2009-11-13 JP JP2011536535A patent/JP2012508773A/ja active Pending
- 2009-11-13 CL CL2009002073A patent/CL2009002073A1/es unknown
- 2009-11-13 CN CN2009801536827A patent/CN102271663A/zh active Pending
- 2009-11-13 KR KR1020117013465A patent/KR20110097829A/ko not_active Application Discontinuation
- 2009-11-13 US US12/618,511 patent/US20100151019A1/en not_active Abandoned
- 2009-11-13 AR ARP090104410A patent/AR074347A1/es unknown
- 2009-11-13 WO PCT/US2009/064455 patent/WO2010057036A2/en active Application Filing
- 2009-11-13 BR BRPI0921049A patent/BRPI0921049A2/pt not_active IP Right Cessation
- 2009-11-13 CA CA2743639A patent/CA2743639A1/en not_active Abandoned
- 2009-11-13 TW TW098138684A patent/TW201022253A/zh unknown
- 2009-11-13 RU RU2011123377/15A patent/RU2011123377A/ru unknown
- 2009-11-13 AU AU2009313867A patent/AU2009313867A1/en not_active Abandoned
-
2012
- 2012-10-01 US US13/633,055 patent/US20130172374A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102271663A (zh) | 2011-12-07 |
US20100151019A1 (en) | 2010-06-17 |
RU2011123377A (ru) | 2012-12-20 |
BRPI0921049A2 (pt) | 2017-03-28 |
JP2012508773A (ja) | 2012-04-12 |
WO2010057036A3 (en) | 2011-06-09 |
US20130172374A1 (en) | 2013-07-04 |
TW201022253A (en) | 2010-06-16 |
AR074347A1 (es) | 2011-01-12 |
AU2009313867A1 (en) | 2011-06-30 |
WO2010057036A2 (en) | 2010-05-20 |
CA2743639A1 (en) | 2010-05-20 |
KR20110097829A (ko) | 2011-08-31 |
EP2376065A2 (en) | 2011-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009002073A1 (es) | Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares. | |
CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
ES2557303T3 (es) | Agente terapéutico para la estenosis del canal espinal | |
RS52367B (en) | GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES | |
AR065246A1 (es) | Composiciones para mejorar la absorcion gastrointestinal de nutrientes y de farmacos | |
ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
CL2011000170A1 (es) | Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa. | |
CL2008000219A1 (es) | Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento | |
LTPA2019508I1 (lt) | Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui | |
CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
AR081520A1 (es) | Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo | |
CL2009001077A1 (es) | Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo. | |
WO2006008173A3 (en) | Pharmaceutical formulations for inhalation | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
TR201904884T4 (tr) | Koloni̇k boşaltmada kullanima yöneli̇k formülasyonlar ve formülasyonlarin üreti̇m yöntemleri̇ | |
AR064104A1 (es) | Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas | |
CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
AR067048A1 (es) | Formulaciones acuosas de acetaminofen para inyeccion. | |
UY31059A1 (es) | Formulaciones de aminoacido n-halogenado | |
EA201270745A1 (ru) | Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона | |
PE20050439A1 (es) | Forma de dosificacion farmaceutica de liberacion prolongada | |
ECSP099251A (es) | Formulaciones farmacéuticas | |
UY30126A1 (es) | Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones |